XBiotech Inc. Reports Director/Officer Changes & Compensation
Ticker: XBIT · Form: 8-K · Filed: Dec 31, 2024 · CIK: 1626878
| Field | Detail |
|---|---|
| Company | Xbiotech Inc. (XBIT) |
| Form Type | 8-K |
| Filed Date | Dec 31, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, corporate-governance
Related Tickers: XBIO
TL;DR
XBIO board shakeup and exec comp changes filed 12/31.
AI Summary
XBiotech Inc. filed an 8-K on December 31, 2024, reporting changes related to its board of directors and officers, including the departure of certain individuals and the election of new directors. The filing also covers compensatory arrangements for its officers. The company is incorporated in British Columbia, Canada, with its principal executive offices located in Austin, Texas.
Why It Matters
Changes in a company's board and executive officers can signal shifts in strategy or governance, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in directors and officers, especially if frequent or unexplained, can indicate internal instability or strategic shifts that may pose risks.
Key Players & Entities
- XBiotech Inc. (company) — Registrant
- December 31, 2024 (date) — Date of earliest event reported
- Austin, Texas (location) — Principal executive offices
- British Columbia, Canada (location) — State of Incorporation
FAQ
What specific changes were made to the board of directors and officer positions?
The filing indicates the departure of certain directors or officers and the election of new directors, along with information on compensatory arrangements for certain officers, but does not detail the specific individuals involved or the exact nature of the changes in this section.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on December 31, 2024.
Where are XBiotech Inc.'s principal executive offices located?
XBiotech Inc.'s principal executive offices are located at 5217 Winnebago Lane, Austin, TX 78744.
Under which sections of the Securities Exchange Act is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is XBiotech Inc.'s Standard Industrial Classification (SIC) code?
XBiotech Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 669 words · 3 min read · ~2 pages · Grade level 10.8 · Accepted 2024-12-31 15:22:04
Filing Documents
- f8k_123124.htm (8-K) — 24KB
- 0001171843-24-007128.txt ( ) — 191KB
- xbit-20241231.xsd (EX-101.SCH) — 3KB
- xbit-20241231_lab.xml (EX-101.LAB) — 33KB
- xbit-20241231_pre.xml (EX-101.PRE) — 24KB
- f8k_123124_htm.xml (XML) — 3KB
02 Departure of Directors or Certain
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. XBiotech Inc. (the Company) announces the December 24, 2024 appointment of Tak W. Mak, Ph.D. to the Company's Board of Directors. Pursuant to Section 14.4 of the Company's Articles, the Board has appointed Dr. Mak to fill the existing vacancy on the board. Dr. Mak will serve until the next annual general meeting and will receive similar compensation to the other members. Dr. Mak is a world-renowned scientist who serves as a professor in the Departments of Medical Biophysics and Immunology at the University of Toronto and has been inducted into the Canadian Medical Hall of Fame. In 1984, he identified and cloned the T cell receptor, which advanced basic and applied fields of immunology and opened the door for the development of modern immunotherapies. In 1993, Dr. Mak launched the Amgen Research Institute in Toronto, firmly establishing Toronto as one of the world's leading centers of biomedical research. Dr. Mak's work led to medical innovation that changed the foundation of oncology—identification of the immune checkpoint inhibitor CTLA-4, has become one of the most important therapeutic targets in oncology today. Dr. Mak cofounded Agios Pharmaceuticals, a cellular metabolism-focused biotechnology company that has developed multiple FDA-approved cancer treatments. The Cancer Research Institute awarded Dr. Mak the 2023 William B. Coley Award for Distinguished Research in Basic and Tumor Immunology, which is the CRI's highest scientific honor. John Simard, President and CEO of XBiotech, commented, "We enthusiastically welcome Dr. Mak to our Board of Directors. Tak is an extraordinary scientist and innovator and we are very fortunate to have him as part of our team." Independent directors W. Thorpe McKenzie and Jan-Paul Waldin will continue to serve as members of the Company's Audit Committee. The Company int
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 31, 2024 XBIOTECH INC. By: /s/John Simard John Simard Chief Executive Officer and President